KR101113067B1 - Composition for preparing alkali water and method for producing alkali water using the same - Google Patents
Composition for preparing alkali water and method for producing alkali water using the same Download PDFInfo
- Publication number
- KR101113067B1 KR101113067B1 KR1020090012605A KR20090012605A KR101113067B1 KR 101113067 B1 KR101113067 B1 KR 101113067B1 KR 1020090012605 A KR1020090012605 A KR 1020090012605A KR 20090012605 A KR20090012605 A KR 20090012605A KR 101113067 B1 KR101113067 B1 KR 101113067B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkaline water
- water
- present
- mineral composition
- producing
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 265
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 25
- 239000003513 alkali Substances 0.000 title description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 94
- 235000010755 mineral Nutrition 0.000 claims abstract description 94
- 239000011707 mineral Substances 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 29
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 28
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims abstract description 28
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000001527 calcium lactate Substances 0.000 claims abstract description 14
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 14
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 14
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 14
- 229910000027 potassium carbonate Inorganic materials 0.000 claims abstract description 14
- 239000001103 potassium chloride Substances 0.000 claims abstract description 14
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 239000001509 sodium citrate Substances 0.000 claims abstract description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 12
- 239000008213 purified water Substances 0.000 claims description 35
- 238000002156 mixing Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 229920000877 Melamine resin Polymers 0.000 abstract description 26
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 22
- 210000004369 blood Anatomy 0.000 abstract description 21
- 239000008280 blood Substances 0.000 abstract description 21
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 10
- 229930006000 Sucrose Natural products 0.000 abstract description 10
- 235000011147 magnesium chloride Nutrition 0.000 abstract description 6
- 235000011181 potassium carbonates Nutrition 0.000 abstract description 6
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000001301 oxygen Substances 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 238000005868 electrolysis reaction Methods 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 229960005069 calcium Drugs 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000035622 drinking Effects 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- -1 hydroxide ions Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000009422 growth inhibiting effect Effects 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 241001103617 Pseudomonas aeruginosa ATCC 15442 Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 244000000028 waterborne pathogen Species 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/154—Water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1578—Calcium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/16—Potassium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/161—Magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1638—Undefined mineral extract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 알칼리수 제조용 미네랄 조성물 및 이를 이용한 알칼리수의 제조방법에 관한 것이다. 보다 구체적으로, 본 발명은 염화칼륨, 탄산칼륨, 염화마그네슘, 젖산칼슘 및 물을 포함하는 알칼리수 제조용 미네랄 조성물, 상기 조성물에 구연산나트륨, 정백당, 정제포도당을 추가로 포함하는 것을 특징으로 하는 알칼리수 제조용 미네랄 조성물 및 이를 이용한 알칼리수의 제조방법에 관한 것이다. 본 발명에 따른 알칼리수 제조용 미네랄 조성물을 이용한 알칼리수의 제조방법은 알칼리수를 얻기 위해 종래에 요구되었던 별도의 설비가 필요하지 않기 때문에 경제적 효과가 우수할 뿐만 아니라 그 실용적 가치를 높이는 효과가 있다. 또한, 본 발명의 방법에 의해 제조된 알칼리수는 종래의 알칼리수에 비해 항균활성이 우수할 뿐만 아니라 낮은 산화환원전위 값 및 높은 pH값을 가지며 혈중의 활성산소 농도를 감소시키는 효과 및 멜라민을 분해할 수 있는 효과가 있다. The present invention relates to a mineral composition for producing alkaline water and a method for producing alkaline water using the same. More specifically, the present invention is a mineral composition for producing alkaline water comprising potassium chloride, potassium carbonate, magnesium chloride, calcium lactate and water, mineral composition for producing alkaline water, characterized in that the composition further comprises sodium citrate, white sugar, refined glucose And it relates to a method for producing alkaline water using the same. The method for producing alkaline water using the mineral composition for producing alkaline water according to the present invention does not require a separate facility, which is conventionally required to obtain alkaline water, so that the economic effect is excellent and the practical value is increased. In addition, the alkaline water prepared by the method of the present invention not only has superior antibacterial activity compared to conventional alkaline water, but also has a low redox potential value and a high pH value, and can decompose melamine and the effect of reducing the concentration of free radicals in the blood. It has an effect.
알칼리수, 미네랄, 항균활성, 활성산소, 산화환원전위 Alkaline water, minerals, antibacterial activity, free radicals, redox potential
Description
본 발명은 알칼리수 제조용 미네랄 조성물 및 이를 이용한 알칼리수의 제조방법에 관한 것이다. 보다 구체적으로, 본 발명은 염화칼륨, 탄산칼륨, 염화마그네슘, 젖산칼슘 및 물을 포함하는 것을 특징으로 하는 알칼리수 제조용 미네랄 조성물 및 이를 이용한 알칼리수의 제조방법에 관한 것이다.The present invention relates to a mineral composition for producing alkaline water and a method for producing alkaline water using the same. More specifically, the present invention relates to a mineral composition for producing alkaline water and a method for producing alkaline water using the same, comprising potassium chloride, potassium carbonate, magnesium chloride, calcium lactate, and water.
일반적으로 물은 상온에서 색, 냄새 및 맛이 없는 액체로서, 화학적으로는 산소와 수소의 결합물을 말한다. 이러한 물은 인류를 비롯한 모든 생물체에 있어서 가장 필요한 물질이라 할 수 있는데 특히 인간의 몸의 여러 부분에서 물이 차지하는 비율을 살펴보면 혈액은 80%가 물이며, 심장은 약 79%, 비장과 근육 및 뇌도 약 75%가 물로 되어 있다. 따라서 물은 산소와 더불어 인간 생존에 가장 필수적인 요소라 할 수 있다.Generally, water is a liquid without color, smell and taste at room temperature, and chemically refers to a combination of oxygen and hydrogen. This water is the most necessary substance for all living things including humans. Especially, when we consider the ratio of water in various parts of the human body, 80% of the blood is water, 79% of the heart, spleen, muscle and brain. About 75% is made of water. Therefore, water, together with oxygen, is the most essential element for human survival.
또한 우리 몸에서 물이 하는 역할은 세포의 형태를 유지하고, 대사작용을 높이며, 혈액과 조직액의 순환을 원활하게 하고, 영양소를 용해시키며 이를 흡수 및 운반해서 필요한 세포로 공급해주고, 체내에서 불필요한 노폐물이나 독소를 체외로 배설시키는 역할을 할 뿐만 아니라, 체내의 열을 발산시켜 체온을 조절하며, 관절 및 뼈마디의 움직임을 원활하게 해주는 윤활유 역할을 하는 등 인체 내에서 매우 중요하고 다양한 역할을 한다. In addition, the role of water in our body is to maintain cell morphology, increase metabolism, facilitate circulation of blood and tissue fluids, dissolve nutrients, absorb and transport it, and supply it to the cells that are needed, In addition to the role of excretion of the toxins outside the body, the body's heat is released by controlling the body temperature, and the role of lubricants to facilitate the movement of joints and bone nodes, and plays a very important role in the human body.
한편, 알칼리수는 높은 pH와 낮은 산화환원전위(Oxidation Reduction Potential:ORP)를 갖도록 처리된 물을 말한다. 높은 pH를 나타내는 알칼리성 물은 산성화된 체액을 알칼리성으로 되돌려 혈액순환을 원활하게 할 수 있으며, 물의 낮은 산화환원전위는 노화의 주요원인으로 알려져 있는 활성산소를 제거할 수 있는 것으로 보고되고 있다. 예를 들어, 전기분해에 의해서 생성되는 pH 8 이상의 알칼리 환원수는 위산과다, 위장 내 이상발효 등에 효능이 있는 점이 인정되었고, 또한 최근 연구에 따르면 동물 실험에서 면역 기능 상승, 항암 효과, 암 전이 억제 효과를 나타냈으며, 당뇨 및 비만 유발 쥐의 혈당치는 물론 몸에 해로운 중성지방과 콜레스테롤 수치도 현저하게 떨어뜨리는 효능이 있는 것으로 보고되면서 음용수 뿐만 아니라 의료 용도로도 사용되고 있다.On the other hand, alkaline water refers to water treated to have a high pH and a low Oxidation Reduction Potential (ORP). Alkaline water exhibiting high pH can return acidified body fluid to alkaline to facilitate blood circulation, and low redox potential of water has been reported to remove active oxygen, which is known to be a major cause of aging. For example, it has been recognized that alkaline reduced water of
또한, 최근에는 미네랄이 함유된 알칼리성을 띤 물이 건강에 매우 좋다는 연구 결과들이 보고되고 있다. 미네랄은 여러 가지 대사활동에 관여하는 필수 영양소에 해당하는 것으로 인체 내에서 자체적으로 생성되지 않으므로 반드시 외부로부터 섭취해야 하는 성분이다. 따라서 알칼리성이며 각종 미네랄 성분이 함유된 물은 우리 몸의 건강과 매우 밀접한 관계가 있기 때문에 평상시 자주 접하는 것이 좋다. 그러나 현대인들의 식생활 습관이 변화하면서 인체에 공급되는 영양소가 불균형해 지고 필요한 미네랄 원소들을 고르게 섭취할 수 없게 됨에 따라 새로운 미네랄 공급원을 필요로 하게 되었다. In addition, recent studies have reported that alkaline water containing minerals is very good for health. Minerals are essential nutrients that are involved in various metabolic activities. They are not produced by the human body and must be taken from the outside. Therefore, alkaline and water containing various minerals are closely related to the health of our body, so it is good to contact them as usual. However, as the dietary habits of modern people change, the nutrients supplied to the human body become unbalanced and the required intake of the necessary mineral elements is not possible. Therefore, a new source of minerals is needed.
이에 미네랄을 함유하는 알칼리수의 제조방법들이 개발되고 있는데, 이와 관련된 종래 기술들을 살펴보면, 대한민국 등록특허 제0654683호에는 동해 심층수의 담수화 및 미네랄 조정을 통하여 미네랄이 풍부한 음용 심층수 및 그 함량을 다양하게 조정하는 제조 장치에 대한 내용이 개시되었고, 대한민국 등록특허 제0543574호에는 바닷물이 담수화된 지하 심층염수로부터 수득한 미네랄 조성물을 포함하는 미네랄수가 개시된 바 있으며, 또한 대한민국 등록특허 제0651654호에는 물을 두차례 전기분해하여 활성수소 및 활성미네랄이 풍부한 알칼리수를 제조할 수 있는 전기분해 정수기에 대한 내용이 개시된 바 있다. Therefore, methods for producing mineral water containing minerals have been developed. Looking at the related arts, Korean Patent No. 0654683 discloses various mineral-rich drinking deep water and its content through desalination and mineral adjustment of deep sea water. The contents of the manufacturing apparatus have been disclosed, and Korean Patent No. 0543574 discloses a mineral water including a mineral composition obtained from deep seawater desalted water, and Korean Patent No. 0651654 discloses water twice. It has been disclosed about the electrolytic water purifier that can be decomposed to produce active water and alkaline water rich in active minerals.
그러나 상기 종래기술에 따른 미네랄 함유 알칼리수의 제조방법들은 바다로부터 심층수를 얻기 위해 고가의 장비 및 오랜 시간의 제조과정과 복잡한 단계들이 필요하며, 물을 전기분해하기 위해서도 전력공급 및 고가의 장비가 별로도 필요하고 별도의 환원제인 촉매가 필요하기 때문에 시간적 및 경제적으로 효율성이 떨어지는 문제점이 있다. 또한, 전기분해를 이용하여 수득한 알칼리수의 경우, 전기는 전자파를 발생하는 원인이 되는 매개체로 물의 성질을 나쁘게 만들 수 있으며, 인체에 유익한 음이온은 모두 산성수로 빠져나가게 되서 이러한 음이온이 존재하지 않는다. 또한 전기분해 알칼리수는 공기 중에 노출되면 급격히 중성으로 되돌아가게 되며 가열하거나 냉각시킬 경우 물속의 미네랄이 침전되는 경우가 발생하는 문제점이 있다. However, the preparation method of the mineral-containing alkaline water according to the prior art requires expensive equipment and a long time manufacturing process and complicated steps in order to obtain deep water from the sea, the power supply and expensive equipment is also required to electrolyze water Since there is a need for a catalyst as a separate reducing agent, there is a problem in that the efficiency is reduced in time and economics. In addition, in the case of alkaline water obtained by using electrolysis, electricity is a medium that generates electromagnetic waves, which can make the water deteriorate, and all anions that are beneficial to the human body escape into acidic water so that these anions do not exist. . In addition, the electrolyzed alkaline water is rapidly returned to neutral when exposed to air, there is a problem that the minerals in the water is precipitated when heated or cooled.
이에 본 발명자들은 별도의 설비가 요구되지 않으면서 손쉽게 알칼리수를 제조할 수 있는 방법을 연구한 결과, 염화칼륨, 탄산칼륨, 염화마그네슘, 구연산나트륨, 젖산칼슘, 정백당 및 정제포도당을 포함하는 알칼리수 제조용 미네랄 조성물을 이용하여 알칼리수를 제조하는 방법을 개발하였고 본 발명의 방법에 따라 제조된 알칼리수가 종래의 알칼리수에 비해 산화환원전위가 낮고 뛰어난 세균 증식 억제 효과가 있을 뿐만 아니라 혈중의 활성산소 농도를 감소시키는 효과 및 멜라민을 분해하는 효과가 있는 것을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors have studied a method for producing alkaline water easily without requiring additional equipment. As a result, mineral composition for preparing alkaline water including potassium chloride, potassium carbonate, magnesium chloride, sodium citrate, calcium lactate, white sugar and refined glucose Has developed a method for producing alkaline water, and the alkaline water prepared according to the method of the present invention has a low redox potential and excellent bacterial growth inhibitory effect as compared to the conventional alkaline water, and also reduces the concentration of free radicals in the blood and The present invention was completed by confirming that there was an effect of decomposing melamine.
따라서 본 발명의 목적은 염화칼륨, 탄산칼륨, 염화마그네슘, 젖산칼슘 및 물을 포함하는 알칼리수 제조용 미네랄 조성물을 제공하는 것이다. It is therefore an object of the present invention to provide a mineral composition for producing alkaline water comprising potassium chloride, potassium carbonate, magnesium chloride, calcium lactate and water.
본 발명의 다른 목적은 상기 조성물을 이용한 알칼리수의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing alkaline water using the composition.
본 발명의 또 다른 목적은 상기 방법으로 제조된 알칼리수를 제공하는 것이다.Another object of the present invention is to provide alkaline water prepared by the above method.
상기와 같은 본 발명의 목적을 달성하기 위해서, 본 발명은In order to achieve the object of the present invention as described above, the present invention
정제수 100 중량부에 대해 염화칼륨 8~10 중량부, 탄산칼륨 40~60 중량부, 염화마그네슘 1~2 중량부 및 젖산칼슘 1~2 중량부를 포함하는 알칼리수 제조용 미네랄 조성물 및 상기 조성물에 구연산나트륨 3~7 중량부, 정백당 15~30 중량부 및 정제포도당 2~5 중량부를 추가로 포함하는 것을 특징으로 하는 알칼리수 제조용 미네랄 조성물을 제공한다. Mineral composition for producing alkaline water comprising 8 to 10 parts by weight of potassium chloride, 40 to 60 parts by weight of potassium carbonate, 1 to 2 parts by weight of magnesium chloride and 1 to 2 parts by weight of calcium lactate, and sodium citrate in the composition. It provides a mineral composition for producing alkaline water, characterized in that it further comprises 7 parts by weight, 15-30 parts by weight per white and 2 to 5 parts by weight of refined glucose.
또한, 본 발명은 In addition,
(a) 본 발명에 따른 상기 알칼리수 제조용 미네랄 조성물을 가열한 정제수와 혼합하는 단계;(a) mixing the mineral composition for producing alkaline water with heated purified water according to the present invention;
(b) 상기 (a) 단계에서 제조된 용액을 여과시킨 후, 여과된 용액을 다시 상온의 정제수와 혼합하는 단계; 및(b) filtering the solution prepared in step (a), and then mixing the filtered solution with purified water at room temperature again; And
(c) 상기 (b) 단계에서 혼합한 용액을 100℃~125℃에서 30초~10분간 가열살균하는 단계를 포함하는 알칼리수의 제조방법을 제공한다.(c) it provides a method of producing alkaline water comprising the step of heat sterilization of the solution mixed in step (b) at 100 ℃ ~ 125 ℃ 30 seconds to 10 minutes.
나아가, 본 발명은 상기 방법에 의해 제조된 알칼리수 제조용 미네랄 조성물을 이용한 알칼리수를 제공한다.Furthermore, the present invention provides alkaline water using the mineral composition for producing alkaline water prepared by the above method.
본 발명에 따른 알칼리수 제조용 미네랄 조성물을 이용한 알칼리수의 제조방법은 알칼리수를 얻기 위해 종래에 요구되었던 별도의 장치 및 환원제가 필요하지 않기 때문에 시간적 및 경제적 효과가 우수할 뿐만 아니라 그 실용적 가치를 높이는 효과가 있다. 또한, 본 발명의 방법에 의해 제조된 알칼리 수는 종래의 알칼리 수에 비해 산화환원전위가 낮으며 뛰어난 세균 증식 억제 효과가 있고 혈중의 활성산소 농도를 감소시키는 효과가 있다.Alkaline water production method using the mineral composition for producing alkaline water according to the present invention is not only need a separate device and reducing agent conventionally required to obtain alkaline water, it is not only excellent in time and economic effect, it is effective to increase the practical value. . In addition, the alkali water produced by the method of the present invention has a lower redox potential than the conventional alkali water, has an excellent bacterial growth inhibitory effect, and reduces the active oxygen concentration in the blood.
본 발명은 염화칼륨, 탄산칼륨, 염화마그네슘, 젖산칼슘 및 물을 포함하는 알칼리수 제조용 미네랄 조성물 및 상기 조성물에 구연산나트륨, 정백당 및 정제포도당을 추가로 포함하는 것을 특징으로 하는 알칼리수 제조용 미네랄 조성물을 제공한다. 보다 바람직하게는, 정제수 100 중량부에 대해 염화칼륨 8~10 중량부, 탄산칼륨 40~60 중량부, 염화마그네슘 1~2 중량부 및 젖산칼슘 1~2 중량부를 포함하는 알칼리수 제조용 미네랄 조성물, 상기 조성물에 구연산나트륨 3~7 중량부, 정백당 15~30 중량부 및 정제포도당 2~5 중량부를 추가로 포함하는 것을 특징으로 하는 알칼리수 제조용 미네랄 조성물을 제공한다.The present invention provides a mineral composition for producing alkaline water, including potassium chloride, potassium carbonate, magnesium chloride, calcium lactate, and water, and a mineral composition for producing alkaline water, further comprising sodium citrate, white sugar, and purified glucose. More preferably, the mineral composition for producing alkaline water comprising 8 to 10 parts by weight of potassium chloride, 40 to 60 parts by weight of potassium carbonate, 1 to 2 parts by weight of magnesium chloride and 1 to 2 parts by weight of calcium lactate based on 100 parts by weight of purified water, the composition To provide a mineral composition for producing alkaline water, characterized in that it further comprises 3 to 7 parts by weight of sodium citrate, 15 to 30 parts by weight per white and 2 to 5 parts by weight of refined glucose.
본 발명의 일실시예에서는 정제수 1ℓ를 기준으로 염화칼륨 80~100g, 탄산칼륨 400~600g, 염화마그네슘 10~20g, 구연산나트륨 30~70g, 젖산칼슘 10~20g, 정백당 150~300g 및 정제포도당 20~50g을 첨가하고 용해하여 이온화시킴으로써 알칼리수 제조용 미네랄 조성물을 제조하였다. In one embodiment of the present invention, based on 1 liter of purified water, potassium chloride 80-100 g, potassium carbonate 400-600 g, magnesium chloride 10-20 g, sodium citrate 30-70 g, calcium lactate 10-20 g, white sugar 150-300 g and refined glucose 20- A mineral composition for producing alkaline water was prepared by adding 50 g, dissolving and ionizing.
상기 제조된 본 발명에 따른 알칼리수 제조용 미네랄 조성물은 세균, 효모 및 곰팡이 등 광범위한 종류의 균주들에 대해 강력한 항균 활성을 갖는 특징이 있다. 본 발명의 일실험예에서는 본 발명의 알칼리수 제조용 미네랄 조성물이 대장균에 대해서는 약 99.8%의 사멸효과 및 녹농균에 대해서는 약 99.7%의 사멸효과를 갖는 것을 확인할 수 있었다(도 1 참조).The mineral composition for producing alkaline water according to the present invention is characterized by having a strong antimicrobial activity against a wide range of strains, such as bacteria, yeast and mold. In one experimental example of the present invention, it was confirmed that the mineral composition for producing alkaline water of the present invention had a killing effect of about 99.8% for E. coli and about 99.7% for Pseudomonas aeruginosa (see FIG. 1).
또한, 본 발명에 따른 알칼리수 제조용 미네랄 조성물을 이용하여 제조한 알칼리수 역시 종래의 알칼리수에 비해 월등히 우수한 항균 활성을 갖는 특징이 있다. 특히, 본 발명의 일실험예에서는 입속 세균들을 대상으로 본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조한 알칼리수와 시중에 판매되고 있는 알칼리수의 입속 세균 증식 억제 효과를 비교한 결과, 본 발명에 따른 알칼리수가 종래의 알칼리수에 비해 세균증식의 억제율이 약 7배~8배 우수한 것을 알 수 있었다(도 2 참조). In addition, the alkaline water prepared by using the mineral composition for producing alkaline water according to the present invention also has an excellent antibacterial activity as compared to the conventional alkaline water. In particular, in one experimental example of the present invention, as a result of comparing the effect of inhibiting the oral bacteria growth in the oral cavity of alkaline water prepared by using the mineral composition for producing alkaline water of the present invention and alkaline water on the market, alkaline water according to the present invention It was found that the suppression rate of bacterial growth is about 7 to 8 times superior to the conventional alkaline water (see Fig. 2).
또한, 본 발명의 알칼리수 제조용 미네랄 조성물은 상기 조성물을 이용하여 알칼리수를 제조할 경우, 상기 알칼리수의 pH 값을 높게 유지하여 알칼리성을 띄게 하며, 산화환원전위 값을 낮추어 강한 환원력을 갖게 하는 특징이 있다. 본 발명의 일실험예에서는 본 발명의 방법으로 제조된 알칼리수와 종래의 전기분해 장치를 이 용하여 제조된 알칼리수의 산화환원전위 값 및 pH값을 각각 측정하여 비교한 결과, 본 발명의 알칼리수가 종래의 알칼리수에 비해 월등히 낮은 산화환원전위 값 및 높은 pH값을 나타내는 것을 확인할 수 있었다.In addition, the mineral composition for producing alkaline water of the present invention is characterized in that when the alkaline water is prepared using the composition, it maintains the pH value of the alkaline water to have high alkalinity, and has a strong reducing power by lowering the redox potential value. In an experimental example of the present invention, the alkali water of the present invention was measured by comparing the redox potential value and the pH value of the alkaline water prepared by the method of the present invention with the conventional electrolysis device. Compared with alkaline water, it was confirmed that it showed much lower redox potential value and high pH value.
따라서 본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조한 알칼리수를 소비자들이 음용할 경우, 산성화된 체액을 알칼리성으로 되돌려 혈액순환을 원활하게 하며, 노화의 주요 원인으로 알려진 활성산소를 제거할 수 있는 효과가 있음을 예상할 수 있었다.Therefore, when consumers drink the alkaline water prepared by using the mineral composition for producing alkaline water of the present invention, the acidified body fluid is returned to alkaline to facilitate blood circulation, and has the effect of removing active oxygen, which is known as a major cause of aging. Could be expected.
한편, 활성산소란 생명유지에 절대적으로 필요한 산소이지만, 안정한 분자상태인 기저삼중항산소(Ground State Triplet Oxygen)가 체내 효소계, 환원대사, 공해물질, 광화학 반응 등의 물리적, 화학적 및 환경적 요인으로 인하여 반응성이 매우 큰 활성산소(Active Oxygen)로 전환되어 인체에 치명적인 산화독성을 야기한다. 또한, 활성산소는 세포구성 성분인 지질, 단백질, 당, DNA등에 대하여 비선택적, 비가역적 파괴 작용을 초래하여 노화현상은 물론 암을 비롯한 각종질병을 일으키는 원인으로 알려져 있다(Free Radical Theory, 1954년, Denhum Harman). 따라서 활성산소에 의해 초래되는 질병을 예방하고 치료하기 위해서는 일차적으로 체내에서 과도하게 발생하는 활성산소의 농도를 감소시키는 일이 매우 중요하다. On the other hand, active oxygen is oxygen that is absolutely necessary for life support, but the stable state of the ground triple oxygen (Ground State Triplet Oxygen) is a physical, chemical and environmental factors such as enzymes, reducing metabolism, pollutants, photochemical reactions in the body Due to the conversion to very active oxygen (Active Oxygen) it causes oxidative toxicity fatal to the human body. In addition, free radicals are known to cause non-selective and irreversible destruction of cell components such as lipids, proteins, sugars, and DNA, causing aging and various diseases including cancer ( Free Radical Theory , 1954). , Denhum Harman). Therefore, in order to prevent and treat diseases caused by free radicals, it is very important to first reduce the concentration of free radicals excessively generated in the body.
이에 본 발명자들은 본 발명의 방법으로 제조된 알칼리수가 체내의 활성산소 농도를 감소시키는지 확인하기 위하여, 본 발명에 따른 알칼리수 및 종래의 알칼리수를 각각 실험요원들에게 음용하게 한 후, 혈중 활성산소의 농도를 측정하여 비교하였다. 그 결과, 본 발명의 방법으로 제조된 알칼리수가 종래의 알칼리수에 비해 혈중의 활성산소를 감소시키는 효과가 더 우수한 것을 확인할 수 있었다(도 3 참조). 따라서 본 발명의 알칼리수 제조용 미네랄 조성물은 혈중의 활성산소 농도를 감소시키는 특징이 있다.Therefore, the inventors of the present invention in order to determine whether the alkaline water prepared by the method of the present invention to reduce the concentration of active oxygen in the body, after drinking the alkaline water and the conventional alkaline water according to the present invention to each of the experimental personnel, The concentrations were measured and compared. As a result, it was confirmed that the alkaline water produced by the method of the present invention is more effective in reducing the active oxygen in the blood than the conventional alkaline water (see Fig. 3). Therefore, the mineral composition for producing alkaline water of the present invention is characterized by reducing the concentration of free radicals in the blood.
멜라민(melamine)이란 염기성 유기화학물질로 열에 강한 플라스틱 원료의 생산에 사용되는 물질로서 1958년에 비단백질 질소원으로 소의 사료로 사용된 바 있으나 1978년 다른 비단백질 질소원(예컨대, 요소 또는 면실)에 비해 분해 능력이 저조하다는 이유로 사용 금지되었다. 또한, 멜라민은 식품제조 및 가공에 사용할 수 없는 물질로서 유럽식품안정청은 안정성 기준을 초과하여 멜라민을 섭취할 경우 신장염, 신장 결석 등의 유해영향 발생이 우려되는 것으로 평가한 바 있다. 그러나 최근 들어 이러한 멜라민 성분이 안정성 기준을 초과하여 함유된 식품이 다량으로 검출됨에 따라 소비자들의 건강을 위협하고 있는 실정이다. Melamine is a basic organic chemical used for the production of heat-resistant plastic raw materials. Melamine was used as a non-protein nitrogen source in 1958 as a bovine feed, but compared to other non-protein nitrogen sources (eg, urea or cottonseed) in 1978. It was banned due to its low degradation capacity. In addition, melamine is a substance that cannot be used in food manufacturing and processing, and the European Food Safety Administration assessed that ingestion of melamine exceeding stability standards may cause harmful effects such as nephritis and kidney stones. However, recently, a large amount of foods containing such melamine ingredients exceeding the safety standards are threatening the health of consumers.
이에 본 발명자들은 중국산 분유에서 멜라민이 검출되어 세계적으로 멜라민 파동이 야기됨에 따라 본 발명의 방법으로 제조된 알칼리수가 멜라민을 분해할 수 있는 효과가 있는지를 조사하였다. 그 결과, 본 발명의 알칼리수가 멜라민을 매우 효과적으로 분해하는 효과가 있음을 확인할 수 있었다(도 4 참조).The present inventors investigated whether the alkaline water produced by the method of the present invention can decompose melamine as melamine is detected in Chinese milk powder and causes a worldwide melamine wave. As a result, it was confirmed that the alkaline water of the present invention has an effect of decomposing melamine very effectively (see FIG. 4).
본 발명에 따른 조성물은 분말, 과립, 정제, 환제, 당의정제, 캡슐제, 액제, 겔제, 시럽제, 슬러리제, 현탁액 및 주사제 등으로 당업계에 공지된 방법을 이용하여 제형화 될 수 있다. Compositions according to the invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions and injections.
나아가 본 발명은 상기 본 발명의 알칼리수 제조용 미네랄 조성물을 이용한 알칼리수의 제조방법을 제공한다.Furthermore, the present invention provides a method for producing alkaline water using the mineral composition for producing alkaline water of the present invention.
본 발명에 따른 알칼리수 제조용 미네랄 조성물을 이용한 알칼리수의 제조방법을 단계별로 설명하면 다음과 같다. When explaining the step of producing alkaline water using the mineral composition for producing alkaline water according to the present invention.
제1단계: Step 1: 알칼리수Alkaline water 제조용 미네랄 조성물의 제조 Preparation of the preparation mineral composition
본 발명에 따른 알칼리수를 제조하기 위해 먼저 알칼리 미네랄을 이온화시킨 알칼리수 제조용 미네랄 조성물을 제조한다.In order to prepare alkaline water according to the present invention, a mineral composition for preparing alkaline water is first prepared by ionizing an alkali mineral.
보다 구체적으로, 정제수 1ℓ를 기준으로 염화칼륨 80~100g, 탄산칼륨 400~600g, 염화마그네슘 10~20g, 구연산나트륨 30~70g, 젖산칼슘 10~20g, 정백당 150~300g 및 정제포도당 20~50g을 첨가하고 용해하여 이온화시킴으로써 알칼리수 제조용 미네랄 조성물을 제조한다.More specifically, based on 1 liter of purified water, 80 to 100 g of potassium chloride, 400 to 600 g of potassium carbonate, 10 to 20 g of magnesium chloride, 30 to 70 g of sodium citrate, 10 to 20 g of calcium lactate, 150 to 300 g of white sugar and 20 to 50 g of refined glucose are added. A mineral composition for producing alkaline water is prepared by dissolving and ionizing the solution.
알칼리수 제조용 미네랄 조성물을 제조하기 위한 물은 물속에 존재하는 원생생물 및 이물질이 제거되도록 취수원에서 보내진 원수를 당업계에 공지된 방법에 따라 정제할 수 있다. 바람직하게는 여과를 통해 수행할 수 있으며, 더욱 바람직하게는 활성탄 여과조 또는 초정밀 여과 장치를 이용하여 수행할 수 있다. The water for preparing the mineral composition for producing alkaline water can be purified according to methods known in the art to remove the raw water from the intake source to remove the protists and foreign substances present in the water. Preferably, it may be carried out through filtration, and more preferably, it may be performed using an activated carbon filtration tank or an ultra-precision filtration device.
이후, 여과를 통해 이질이 제거된 정제수에 미네랄 물질을 용해시켜 알칼리수 제조용 미네랄 조성물을 제조할 수 있으며, 본 발명에 따른 알칼리수 제조용 미네랄 조성물은 물속에서 이온화되어 알칼리성을 띄는 칼륨, 나트륨, 마그네슘 및 칼슘의 미네랄 성분들을 포함한다.Subsequently, the mineral composition may be prepared by dissolving the mineral substance in purified water from which foreign substances have been removed through filtration, and the mineral composition for preparing alkaline water according to the present invention may be ionized in water to show alkalinity of potassium, sodium, magnesium, and calcium. Contains mineral ingredients.
따라서 본 발명은 인체에 유익한 미네랄 성분을 함유하는 미네랄 용액을 음용수의 제조에 사용하기 때문에 종래에 판매되고 있는 음용수에 비해 건강에 보다 유익할 수 있다. Therefore, since the present invention uses a mineral solution containing mineral components beneficial to the human body in the preparation of drinking water, it may be more beneficial to health than drinking water sold in the prior art.
특히, 본 발명에 사용된 미네랄 성분 중 칼륨은 세포내 액의 주된 양이온으로 세포 외액의 주된 양이온인 나트륨과 함께 삼투압과 수분 평형 조절에 관여하며, 산과 알칼리의 균형 유지에 필수적인 역할을 한다. 그러나 칼륨이 결핍되면 영양부족, 단백질 결핍, 식욕부진 등의 원인이 될 수 있으며, 반면 칼륨을 과잉 섭취하게 되면 만성설사, 갑상선 기능 저하 등을 유발시킬 수 있다. 따라서 본 발명의 알칼리수를 제조하기 위해 사용되는 알칼리수 제조용 미네랄 조성물은 정제수 1000ml에 대하여 염화칼륨을 80~100g 포함하는 것이 바람직하며, 탄산칼륨은 400~600g 포함하는 것이 바람직하다.In particular, potassium in the mineral component used in the present invention is a major cation of intracellular fluids and is involved in the osmotic pressure and water balance control together with sodium, the main cation of extracellular fluids, and plays an essential role in maintaining the balance between acid and alkali. However, lack of potassium can cause malnutrition, protein deficiency, and loss of appetite. On the other hand, excessive potassium can cause chronic diarrhea and hypothyroidism. Therefore, the mineral composition for producing alkaline water used to prepare the alkaline water of the present invention preferably contains 80 to 100 g of potassium chloride, and preferably contains 400 to 600 g of potassium carbonate with respect to 1000 ml of purified water.
상기 나트륨은 칼륨과 함께 삼투압을 조절하는 기능이 있고, 세포의 물질교환에 있어서 중요한 역할을 하며, 정상적인 근육의 자극반응 및 흥분성을 유지하는데 관여한다. 나트륨이 결핍되면 식욕부진, 소화불량, 근육위축, 장내가스 축적 등의 원인이 될 수 있고, 나트륨이 과도하면 피로, 신경불안증, 발작 등을 유발시킬 수 있다. 따라서 본 발명의 알칼리수 제조용 미네랄 조성물은 정제수 1000ml에 대하여 구연산나트륨을 30~70g 포함하는 것이 바람직하다.The sodium, together with potassium, has the function of regulating osmotic pressure, plays an important role in cell mass exchange, and is involved in maintaining normal muscle stimulation and excitability. Lack of sodium can cause anorexia, indigestion, muscle atrophy, and intestinal gas accumulation, and excessive sodium can cause fatigue, anxiety, and seizures. Therefore, it is preferable that the mineral composition for alkaline water manufacture of this invention contains 30-70 g of sodium citrate with respect to 1000 ml of purified water.
칼슘은 체내의 골격계 유지에 가장 중요한 역할을 하며, 근육의 수축과 이완, 효소 활성화 및 면역과 호르몬의 분비조절에 관여한다. 칼슘의 결핍은 성장부진, 우울증, 불면증 및 각종 통증을 유발시키고, 칼슘의 과잉은 식욕감퇴, 체중감소 및 변비 등을 유발시킨다. 한편, 이러한 칼슘은 물과 매우 격렬하게 반응하기 때문에 일반적으로 알칼리수의 제조에 사용이 불가능하다. 그러나 본 발명에서는 적절한 양의 칼슘을 첨가하여 다른 미네랄 성분들과 함께 단시간에 알칼리수를 만들 수 있게 한다. 따라서 이와 같은 점을 고려하여, 본 발명의 알칼리수 제조용 미네랄 조성물은 정제수 1000ml에 대하여 젖산칼슘을 10~20g 포함하는 것이 바람직하다.Calcium plays the most important role in maintaining the skeletal system in the body, and is involved in muscle contraction and relaxation, enzyme activation, and regulation of immunity and hormone secretion. Lack of calcium causes growth, depression, insomnia and various pains, and excess calcium causes loss of appetite, weight loss and constipation. On the other hand, since such calcium reacts very vigorously with water, it cannot generally be used for the production of alkaline water. In the present invention, however, an appropriate amount of calcium can be added to make alkaline water in a short time with other mineral components. Therefore, in view of such a point, it is preferable that the mineral composition for alkali water manufacture of this invention contains 10-20 g of calcium lactate with respect to 1000 ml of purified water.
마그네슘은 세포 대사에 가장 핵심적인 성분으로써, 효소 활성에 중요한 역할을 하며 골격과 치아를 구성한다. 이러한 마그네슘이 결핍되면 신경과민, 경련, 발작 및 동맥경화 등을 유발시키고, 부족하면 혼수, 구토 및 식욕부진 등을 유발시킨다. 또한 마그네슘은 물속에서 물과 반응하여 마그네슘이 산화됨으로써 수산화이온을 형성하게 되고 형성된 수산화이온에 의해 물은 알칼리성을 띄게 되며 동시에 형성된 수소분자에 의해 환원력을 갖게 된다. 따라서 이러한 마그네슘이 본 발명의 조성물에 너무 많은 양으로 포함될 경우, 물속에서 쉽게 산화마그네슘으로 산화되어 마그네슘 표면에 산화막을 형성하기 때문에 알칼리수를 만드는 능력이 급속이 낮아지게 되며, 반면 너무 적은 양으로 포함될 경우 알칼리수 생성 능력의 효과가 미미한 문제점이 있다. 이와 같은 점을 고려하여 본 발명의 알칼리수 제조용 미네랄 조성물은 정제수 1000ml에 대하여 염화마그네슘을 10~20g 포함하는 것이 바람직하다.Magnesium is the most important component of cellular metabolism, plays an important role in enzyme activity and constitutes the skeleton and teeth. Lack of magnesium causes nerve hypersensitivity, convulsions, seizures and atherosclerosis, and lack of magnesium causes coma, vomiting and anorexia. In addition, magnesium reacts with water in water to form hydroxide ions as the magnesium is oxidized, and water is alkaline due to the hydroxide ions formed, and at the same time, it has a reducing power by the hydrogen molecules formed. Therefore, when such magnesium is included in the composition of the present invention in too much amount, the ability to form alkaline water is rapidly lowered because it is easily oxidized to magnesium oxide in water to form an oxide film on the surface of magnesium, whereas when included in too small amount There is a problem that the effect of the alkaline water generating ability is insignificant. In consideration of such a point, the mineral composition for producing alkaline water of the present invention preferably contains 10 to 20 g of magnesium chloride with respect to 1000 ml of purified water.
나아가, 정백당 및 포도당은 이온화된 미네랄 성분들이 재결합하는 것을 방지하여 용액을 안정화시키는 역할을 한다. 따라서 본 발명의 알칼리수 제조용 미네랄 조성물은 정제수 1000ml에 대하여 정백당을 150~300g 포함하는 것이 바람직하고, 정제포도당은 20~50g 포함하는 것이 바람직하다.Furthermore, white sugar and glucose serve to stabilize the solution by preventing the ionized mineral components from recombining. Therefore, it is preferable that the mineral composition for alkaline water manufacture of this invention contains 150-300 g of white sugar with respect to 1000 ml of purified water, and it is preferable that 20-50 g of refined glucose is included.
제2단계: Second step: 알칼리수Alkaline water 제조용 미네랄 조성물을 Mineral composition for manufacturing 정제수와Purified water and 혼합하는 단계 Mixing steps
상기 제1단계에서 제조된 본 발명의 알칼리수 제조용 미네랄 조성물을 가열한 정제수와 혼합한다. The mineral composition for producing alkaline water of the present invention prepared in the first step is mixed with heated purified water.
상기 알칼리수 제조용 미네랄 조성물과 가열한 정제수를 혼합하는 비율은 알칼리수 제조용 미네랄 조성물에 대하여 가열한 정제수를 1:2~1:10의 부피비로 혼합할 수 있다. 이때 상기 가열한 정제수를 사용하는 이유는 차가운 정제수를 사용할 경우, 미네랄 성분들이 완전히 용해되지 않은 채 침전물로 남아있을 수 있기 때문이며, 따라서 상기 가열은 혼합된 미네랄 성분들이 침전되지 않을 정도로 정제수를 가열하는 것이 바람직하며, 더욱 바람직하게는 50℃ 내지 60℃의 온도로 가열하는 것이 바람직하다. The ratio of mixing the mineral composition for producing alkaline water and the heated purified water may be mixed in a volume ratio of 1: 2 to 1:10 with heated purified water relative to the mineral composition for producing alkaline water. The reason for using the heated purified water is that when cold purified water is used, the mineral components may remain as precipitates without being completely dissolved. Therefore, the heating is to heat the purified water so that the mixed mineral components do not precipitate. Preferably, it is more preferable to heat to the temperature of 50 degreeC-60 degreeC.
제3단계: 여과 및 살균 단계Step 3: Filtration and Sterilization
상기 제2단계에서 제조된 알칼리수 제조용 미네랄 조성물과 가열한 정제수를 혼합한 혼합용액을 여과시킨 후, 다시 상온의 정제수와 혼합한 다음, 상기 용액을 100℃~125℃에서 30초~10분 동안 가열 살균한다. After filtering the mixed solution of the mineral composition for producing alkaline water prepared in the second step and the heated purified water, and then mixed with purified water at room temperature again, the solution is heated for 30 seconds to 10 minutes at 100 ℃ ~ 125 ℃ Sterilize.
상기에서 여과는 미네랄 성분들이 걸러지지 않도록 여과막의 기공 크기가 큰 여과기를 이용하는 것이 바람직하며, 예컨대, 카트리지 여과기 또는 시트 여과기 등을 이용하여 수행할 수 있다. 일반적으로 여과막의 기공 크기는 0.1 내지 20㎛인 것을 사용할 수 있으며, 바람직하게는 0.1 내지 10㎛인 것을 사용할 수 있다.In the above filtration, it is preferable to use a filter having a large pore size of the filtration membrane so that the mineral components are not filtered out. For example, the filtration may be performed using a cartridge filter or a sheet filter. In general, the pore size of the filtration membrane may be used 0.1 to 20㎛, preferably 0.1 to 10㎛ can be used.
또한, 상기 알칼리수 제조용 미네랄 조성물과 가열한 정제수를 혼합한 혼합용액을 상온의 정제수와 혼합하는 비율은 상기 혼합용액에 대하여 상온의 정제수를 1:500~1:1,500의 부피비로 혼합할 수 있다.In addition, the ratio of mixing the mixed solution of the mineral composition for producing alkaline water and heated purified water with purified water at room temperature may be mixed with the purified solution at room temperature in a volume ratio of 1: 500 ~ 1: 500.
상기 과정으로 제조된 혼합용액은 이후 100~125℃에서 30초~10분 동안 가열 살균한 후, 살균과정을 마친 물을 용량별로 적절한 용기에 담아 포장하는 단계를 통해 본 발명에 따른 알칼리수를 제조할 수 있다. The mixed solution prepared by the above process is then heat sterilized for 30 seconds to 10 minutes at 100 ~ 125 ℃, the alkaline water according to the present invention through the step of packing the water after the sterilization process by the appropriate container for each capacity to prepare Can be.
상기 기술된 바와 같이, 본 발명의 방법에 따라 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 알칼리수는 미네랄 함량이 풍부하고 낮은 산화환원전위 값 및 높은 pH값을 가지며 우수한 항균 활성이 있을 뿐만 아니라 혈중 활성산소의 농도를 감소시키는 효과 및 멜라민 분해 효과가 있는 특징이 있다. As described above, the alkaline water prepared using the mineral composition for producing alkaline water according to the method of the present invention is rich in mineral content, has a low redox potential value and a high pH value, and has excellent antibacterial activity as well as It is characterized by the effect of reducing the concentration and the effect of melamine degradation.
이하, 본 발명을 실시예에 의해 상세히 설명하기로 한다. 그러나 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, these examples are intended to illustrate the present invention in more detail, and the scope of the present invention is not limited to these examples.
<< 실시예Example 1 내지 3> 1 to 3
본 발명에 따른 According to the invention 알칼리수Alkaline water 제조용 미네랄 조성물의 제조 Preparation of the preparation mineral composition
하기 표 1과 같은 조성비로 본 발명에 따른 알칼리수 제조용 미네랄 조성물을 제조하였다. 먼저, 정제수 1000ml을 50~60℃로 가온 유지한 후에, 염화칼륨, 탄산칼륨, 염화마그네슘, 구연산나트륨, 젖산칼슘, 정백당 및 정제포도당을 하기 조성 비율에 맞춰 차례로 넣고 서서히 교반하여 용해시킨 다음, 정치하여 안정화시킨 후 여과하여 맑은 연한 미색의 액상으로 제조하였다.To prepare a mineral composition for producing alkaline water according to the present invention in a composition ratio as shown in Table 1. First, 1000 ml of purified water was kept at 50 to 60 ° C., and then potassium chloride, potassium carbonate, magnesium chloride, sodium citrate, calcium lactate, white sugar and refined glucose were added in turn according to the following composition ratio, and gradually stirred to dissolve. After stabilization, the mixture was filtered to give a clear pale liquid phase liquid.
<< 실시예Example 4> 4>
본 발명에 따른 According to the invention 알칼리수Alkaline water 제조용 미네랄 조성물을 이용한 알칼리수의 제조 Preparation of Alkaline Water Using Preparative Mineral Composition
상기 실시예 1 내지 3에서 제조된 알칼리수 제조용 미네랄 조성물들 중 실시예 1의 조성물을 사용하여 하기와 같은 방법으로 알칼리수를 제조하였다. 즉, 50~60℃의 정제수 1000ml에 염화칼륨 100g, 탄산칼륨 600g, 염화마그네슘 20g, 구연산나트륨 50g, 젖산칼슘 20g, 정백당 150g 및 정제포도당 30g이 용해된 미네랄 조성물을 50~60℃로 가열한 정제수 10ℓ와 혼합하였다. 이후 상기 혼합액을 구멍 직경이 0.2㎛인 멤브레인 필터로 여과하여 불순물이 제거된 혼합액을 수득하였고, 상기 여과된 혼합액을 다시 상온의 정제수 15000ℓ와 혼합하였다. 그런 뒤 상기 혼합액을 121℃에서 30초 동안 가열살균 시켰고, 살균을 끝낸 혼합액을 500㎖씩 포장하여 본 발명의 알칼리수를 제조하였다. Alkaline water was prepared in the following manner using the composition of Example 1 among the mineral compositions for producing alkaline water prepared in Examples 1 to 3. That is, 10 l of purified water heated to 50 to 60 ° C in a mineral composition containing 100 g of potassium chloride, 600 g of potassium carbonate, 20 g of magnesium chloride, 20 g of sodium citrate, 20 g of calcium lactate, 150 g of white sugar and 30 g of refined glucose in 1000 ml of purified water at 50 to 60 ° C. Mixed with. Thereafter, the mixed solution was filtered through a membrane filter having a pore diameter of 0.2 μm to obtain a mixed solution from which impurities were removed, and the filtered mixed solution was again mixed with 15000 L of purified water at room temperature. Thereafter, the mixed solution was heat sterilized at 121 ° C. for 30 seconds, and 500 ml of the mixed solution which had been sterilized were packed to prepare alkaline water of the present invention.
<실험예 1>Experimental Example 1
알칼리수Alkaline water 제조용 미네랄 조성물의 항균성 평가 Antimicrobial Evaluation of Manufacturing Mineral Compositions
본 발명의 알칼리수 제조용 미네랄 조성물이 항균활성을 갖는지 조사하기 위하여, 상기 실시예 2의 조성물을 한국건자재시험연구원에 의뢰하여 항균활성을 평가하였고, 평가방법은 수인성 병원균인 대장균(E. coli ATCC 25922)과 녹농균(Pseudomonas aeruginosa ATCC 15442)을 본 발명의 조성물 및 대조군에 접종한 후, 37℃에서 24시간 배양한 다음, 균의 사멸율을 세균 감소율로써 측정하였다. In order to investigate whether the mineral composition for producing alkaline water of the present invention has antimicrobial activity, the composition of Example 2 was commissioned by the Korea Institute of Construction Materials, and the antimicrobial activity was evaluated. The evaluation method was E. coli ATCC 25922, which is a water-borne pathogen. ) And Pseudomonas aeruginosa ATCC 15442 were inoculated into the composition and the control group of the present invention, and then cultured at 37 ° C. for 24 hours, and then the killing rate of the bacteria was measured as a rate of bacterial reduction.
그 결과, 대장균의 경우 본 발명의 조성물이 대조군에 비해 약 99.8%의 세균 억제 활성을 보였고(도 1 참조), 녹농균의 경우에도 본 발명의 조성물이 대조군에 비해 99.7%의 세균 억제 활성이 있는 것으로 나타났다. 따라서 본 발명자들은 본 발명에 따른 알칼리수 제조용 미네랄 조성물이 우수한 항균활성을 가지고 있는 것을 확인함으로써 상기 조성물로 알칼리수를 제조할 경우, 세균들로부터 보다 안전한 음용수인 알칼리수를 제조할 수 있을 것으로 예상할 수 있었다.As a result, in the case of E. coli, the composition of the present invention showed about 99.8% of the bacterial inhibitory activity compared to the control group (see FIG. 1), and in the case of Pseudomonas aeruginosa, the composition of the present invention had 99.7% of the bacterial inhibitory activity compared to the control group. appear. Therefore, the present inventors could confirm that the alkaline composition for producing alkaline water according to the present invention has excellent antimicrobial activity, and when producing alkaline water with the composition, it is possible to prepare alkaline water, which is safer drinking water from bacteria.
<실험예 2>Experimental Example 2
알칼리수 제조용 미네랄 조성물로 제조된 알칼리수의 항균력 측정Determination of the Antibacterial Activity of Alkaline Water Prepared with Mineral Composition for Alkaline Water Production
상기 실시예 4에서 본 발명의 방법에 따라 제조된 알칼리수가 세균증식을 억제하는 항균활성이 있는지를 측정하기 위해, 먼저 본 발명에 의해 제조되어 포장된 알칼리수의 뚜껑을 개봉한 후 시간이 지남에 따라 외부로부터 유입되는 세균들이 증식되어 검출되는지를 확인하였다.In order to determine whether the alkaline water prepared according to the method of the present invention in Example 4 has an antimicrobial activity of inhibiting bacterial growth, first, after opening the lid of the alkaline water prepared and packaged according to the present invention, It was confirmed whether bacteria from outside were proliferated and detected.
그 결과, 하기 표 2에 기재한 바와 같이, 개봉 직후부터 개봉후 36 시간이 지난 후에도 본 발명의 알칼리 수에서는 세균들이 검출되지 않았다.As a result, as shown in Table 2 below, bacteria were not detected in the alkaline water of the present invention even after 36 hours after opening from immediately after opening.
또한, 본 발명자들은 최근 들어 많은 음용수들이 휴대하기 간편한 크기로 포장되어 판매되고 있기 때문에 소비자들이 이러한 음용수들을 그대로 입을 대고 마시는 경우가 빈번하므로 입속으로부터 유래된 세균들이 그대로 제품속에 들어가 증식될 수 있음을 고려하여 본 발명의 알칼리수가 입속 세균들의 증식을 억제하는 활성이 있는지를 측정하였다. 상기 측정은 살균 처리한 증류수로 입안을 헹군 물을 본 발명의 알칼리수 및 시판중인 타사의 알칼리수들과 각각 혼합한 다음 상온에서 시간이 지남에 따라 상기 알칼리수에 존재하는 세균의 수(CFU/ml)를 측정함으로써 수행하였다. 이때 대조군으로는 미네랄을 함유한 알칼리수로 알려진 에비앙(프랑스), 삼다수(대한민국), 스마트워터(미국) 및 아쿠아하이드레이트(미국)를 사용하였으며, 결과는 하기 표 3 및 도2에 나타내었다.In addition, the present inventors consider that many drinking waters are packed and sold in a size that is easy to carry in recent years, so that consumers often drink such drinking water as they are, so that bacteria derived from the mouth can be expanded into the product as it is. It was determined whether the alkaline water of the present invention has an activity of inhibiting the growth of the bacteria in the mouth. The measurement was performed by mixing water rinsed in the sterilized distilled water with the alkaline water of the present invention and other commercially available alkaline water, respectively, and then measuring the number of bacteria (CFU / ml) present in the alkaline water over time at room temperature. It was performed by measuring. At this time, Evian (France), Samdasoo (South Korea), smart water (USA) and aquahydrate (USA), which are known as alkaline water containing minerals, were used, and the results are shown in Table 3 and FIG. 2.
측정 결과, 상기 표 3 및 도 2에 나타낸 바와 같이, 본 발명의 방법에 의해 제조된 알칼리수가 기타 시중에서 판매되고 있는 알칼리수들에 비해 입속세균의 증식을 매우 효과적으로 억제하는 것을 확인할 수 있었고, 특히 입속세균을 알칼리수와 혼합하여 36시간이 지난 후에는 본 발명의 알칼리수에 존재하는 세균의 수가 대조군의 알칼리수에서 존재하는 세균의 수에 비해 약 7배~8배로 적은 것으로 나타났다. As a result of the measurement, as shown in Table 3 and Figure 2, it was confirmed that the alkaline water produced by the method of the present invention inhibits the growth of oral bacteria very effectively compared to other commercially available alkaline water, in particular After 36 hours of mixing bacteria with alkaline water, the number of bacteria present in the alkaline water of the present invention was found to be about 7 to 8 times less than the number of bacteria present in the alkaline water of the control group.
<실험예 3>Experimental Example 3
본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 알칼리수의 산화환원전위 측정Measurement of redox potential of alkaline water prepared using the mineral composition for producing alkaline water of the present invention
본 발명자들은 본 발명에 따른 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 상기 실시예 4의 알칼리수 및 전기분해 장치를 이용하여 수득한 알칼리수의 산화환원전위(ORP) 및 pH를 각각 측정하였다. 산화환원전위(ORP) 및 pH의 측정은 pH/DO/ORP(산화환원전위) 측정기(산화환원전위계, 도아데파고교제)를 이용하여 수행하였다. 산화환원전위는 pH/DO/ORP 측정기에 산화환원전위 측정용 전극을 연결하여 측정하였고, pH는 상기 pH/DO/ORP 측정기에 pH 전극을 연결하여 측정하였으며, 그 결과를 하기 표 4에 나타내었다. The present inventors measured the redox potential (ORP) and pH of the alkaline water obtained by using the alkaline water and the electrolysis device of Example 4 prepared using the mineral composition for producing alkaline water according to the present invention, respectively. The measurement of redox potential (ORP) and pH was carried out using a pH / DO / ORP (redox potential) meter (redox potentiometer, Doadepa Co., Ltd.). The redox potential was measured by connecting an electrode for measuring redox potential to a pH / DO / ORP meter, and the pH was measured by connecting a pH electrode to the pH / DO / ORP meter, and the results are shown in Table 4 below. .
그 결과, 상기 표 4에 나타낸 바와 같이, 본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조한 알칼리수는 전기분해장치를 이용하여 제조한 알칼리수에 비해 월등히 낮은 산화환원전위 값 및 월등히 높은 pH 값을 나타내는 것을 확인할 수 있었다.As a result, as shown in Table 4, the alkaline water prepared by using the mineral composition for producing alkaline water of the present invention shows a significantly lower redox potential value and significantly higher pH value than the alkaline water prepared by using an electrolysis device. I could confirm it.
따라서 본 발명자들은 상기 결과를 통해, 본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 알칼리수가 낮은 산화환원전위를 통해 활성산소를 제거할 수 있는 효과 및 이를 통해 산성화된 인체의 pH 균형을 회복시킬 수 있음을 알 수 있었다.Therefore, through the above results, the present inventors can restore the pH balance of the acidified human body, through which the active oxygen can be removed through a redox potential having low alkali water prepared using the mineral composition for producing alkaline water of the present invention. I could see that.
<실험예 4>Experimental Example 4
본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 알칼리수의 혈중 활성산소 농도의 감소효과 측정Determination of the effect of reducing the concentration of active oxygen in the blood of the alkaline water prepared using the mineral composition for producing alkaline water of the present invention
본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조된 알칼리수가 혈액 및 체액을 산성화시켜 성인병 및 여러 가지 질병을 초래하는 활성산소를 제거하는 활성이 있는지를 측정하였다. 이를 위해 실험 요원 7명을 대상으로 상기 실시예 4에서 제조된 본 발명의 알칼리수를 마시게 하였고, 대조군으로 상기 실험예 3에서 사용한 전기분해 장치로 제조된 알칼리수를 마시게 한 후 각각의 집단에 대하여 시간별로 혈중의 활성산소 농도를 측정하였다. 이때 상기 활성산소의 농도 측정은 실험 요원의 손가락 끝에서 검출한 말초혈액을 FORT(free oxygen radicals test, Callegari, Parma, Italy) 테스트 시약을 사용하여 측정하였는데, 즉, 20㎕의 모세관을 사용하여 채혈한 후 시약 R2에 채혈된 모세관을 넣고 큐벳을 조심스럽게 상하로 흔든 다음, 이를 다시 시약 R1에 넣고 큐벳을 1분간 원심분리하여 분리된 혈청을 가지고 측정하였으며, 상기 측정은 활성산소 분석기(FORMox: free oxygen radicals monitor, Callegari, Parma, Italy)를 사용하였다. 또한, 혈중 활성산소 농도 측정은 시간별로 4차례에 걸쳐 수행하였는데, 1차 측정은 알칼리수 복용 전 8시간 공복후 혈액을 채취하여 측정하였고, 2차 측정은 본 발명의 알칼리수 또는 대조군 알칼리수를 복용하게 한 후 40분 동안 충분히 흡수가 이루어지게 한 다음 혈액을 채취하여 측정하였고, 3차 측정은 자전거를 이용하여 2분간 70rpm정도의 가벼운 속도로 페달을 밟기 시작한 후 30초간 전력으로 페달링 운동을 실시한 다음 3분간 휴식을 취하게 하고 다시 30초간 전력으로 페달링 운동을 실시하는 과정을 총 3번 반복 수행하게 하였다. 이러한 무산소성 운동을 마친후 1분이 지난 다음 혈액을 채취하여 측정하였으며, 4차 측정은 상기 3차의 무산소성 운동을 마친후 15분의 휴식 시간 이후에 혈액을 채취하여 측정하였다. It was determined whether the alkaline water prepared using the mineral composition for producing alkaline water of the present invention has an activity for removing free radicals that cause acidic blood and body fluids to cause adult diseases and various diseases. To this end, the experiment was performed to drink the alkaline water of the present invention prepared in Example 4 to 7 experimental personnel, and to each group after drinking the alkaline water prepared by the electrolysis device used in Experimental Example 3 as a control group The concentration of free radicals in blood was measured by time. In this case, the concentration of the active oxygen was measured using a free oxygen radicals test, Callegari, Parma, Italy (FORT) test reagent, which is detected at the fingertips of the test agent. After that, the capillary tube was added to reagent R2, and the cuvet was carefully shaken up and down. Then, the cuvette was added to reagent R1, and the cuvette was centrifuged for 1 minute, and the measured serum was separated. oxygen radicals monitor, Callegari, Parma, Italy). In addition, the measurement of the concentration of free radicals in blood was performed four times per hour, the first measurement was measured by taking blood after fasting for 8 hours before taking alkaline water, the second measurement was to take the alkaline or control alkaline water of the present invention After absorbing enough for 40 minutes, blood was collected and measured, and the third measurement was performed by pedaling at a light speed of about 70 rpm for 2 minutes using a bicycle, and then pedaling with electric power for 30 seconds, and then 3 minutes. Take a break and perform the pedaling exercise with power for 30 seconds again. One minute after the end of the anaerobic exercise, blood was collected and measured, and the fourth measurement was measured by taking the blood after a 15-minute rest period after the third anaerobic exercise.
그 결과, 도 3에 나타낸 바와 같이, 본 발명의 알칼리수를 마신 집단 및 전기분해로 수득한 알칼리수를 마신 대조군의 경우, 각각의 알칼리수를 복용한 다음 40분이 경과된 후에는 모두 혈중 활성산소의 농도가 감소되는 것을 확인할 수 있었다.그러나 무산소성 운동을 실시함에 따라 혈중 증가된 활성산소의 양이 대조군에 비해 본 발명의 알칼리수를 마신 집단에서 월등히 적은 것으로 나타났으며, 운동 완료 후 15분의 휴식 시간이 지난 다음에도 본 발명의 알칼리수를 마신 집단은 혈중의 활성산소 양이 운동전의 수준으로 되돌아왔으나 대조군의 경우에는 운동전보다 높은 활성산소의 양이 그대로 유지되는 것으로 나타났다. As a result, as shown in Fig. 3, in the case of the group who drank the alkaline water of the present invention and the control group which drank the alkaline water obtained by electrolysis, the concentrations of free radicals in the blood were all increased after 40 minutes after the respective alkaline water was taken. However, as the anaerobic exercise was performed, the amount of free radicals increased in the blood was significantly lower in the group who drank the alkaline water of the present invention than in the control group, and the break time of 15 minutes after the exercise was completed was Even after the drinking of the alkaline water of the present invention, the amount of free radicals in the blood returned to the level before exercise, but in the control group, the amount of free radicals was higher than before the exercise.
따라서 상기와 같은 결과를 통해, 본 발명자들은 본 발명의 알칼리수 제조용 미네랄 조성물을 이용하여 제조한 알칼리수가 종래의 알칼리수에 비해 혈중 활성산소의 농도를 감소시키는 효과가 우수하다는 것을 알 수 있었으며, 이로써 소비자들이 본 발명의 알칼리수를 음용할 경우 인체 내에서 산성 노폐물의 생성을 방지할 수 있기 때문에 건강을 증진시킬 수 있음을 알 수 있었다. Therefore, through the above results, the present inventors have found that the alkaline water prepared by using the mineral composition for producing alkaline water of the present invention has an excellent effect of reducing the concentration of free radicals in the blood compared with the conventional alkaline water, thereby allowing consumers to When drinking the alkaline water of the present invention was found to be able to improve the health because it can prevent the production of acidic waste in the human body.
<실험예 5>Experimental Example 5
본 발명의 방법으로 제조된 알칼리수의 멜라민 분해효과 측정Determination of Melamine Degradation Effect of Alkaline Water Prepared by the Method of the Present Invention
본 발명에 따른 알칼리수 제조용 조성물을 이용하여 제조된 알칼리수가 염기성 유기 화합물질인 멜라민(C3H6N6)을 분해하는 효과가 있는지를 조사하였다. 이를 위해 시중에서 판매되고 있는 멜라민을 물에 녹여 1리터에 10ppm의 멜라민 농도가 되도록 하였다. 이후 비이커 5개에 상기 용액을 100ml씩 나눈 뒤, 각 비이커에 본 발명에 따른 알칼리수를 0.1%(v/v), 0.5%(v/v), 1%(v/v), 2%(v/v) 및 5%(v/v)가 되도록 첨가하였다. 이때 대조군으로는 본 발명의 알칼리 수를 첨가하지 않은 것을 사용하였다. 이후 GC-mass 분석기를 이용하여 각 비이커의 멜라민 함량을 측정하였으며, 그 결과를 하기 표 5 및 도 4에 나타내었다.It was examined whether the alkaline water prepared using the composition for producing alkaline water according to the present invention had an effect of degrading melamine (C 3 H 6 N 6 ), which is a basic organic compound. To this end, commercially available melamine was dissolved in water to achieve a melamine concentration of 10 ppm per liter. After dividing the solution into 100 ml each of the five beakers, the alkaline water according to the present invention in each beaker 0.1% (v / v), 0.5% (v / v), 1% (v / v), 2% (v / v) and 5% (v / v). At this time, the control group was used without adding the alkali water of the present invention. Since the melamine content of each beaker was measured using a GC-mass analyzer, the results are shown in Table 5 and FIG.
여기서 멜라민 함량이 1ppm 미만은 식품위생법상 불검출로 표기하였음. Melamine content of less than 1ppm is marked as not detected by the Food Sanitation Law.
그 결과, 상기 표 5에 나타낸 바와 같이, 본 발명에 따른 알칼리수는 멜라민을 분해하는 효과가 있는 것을 확인할 수 있었으며, 특히 1%의 낮은 농도에서도 멜라민의 함량을 54%나 감소시키는 것으로 나타났고, 5%의 경우에는 멜라민의 함량이 검출되지 않는 것으로 나타났다. 따라서 상기 결과를 통해 본 발명의 알칼리수는 멜라민을 분해시키는 효과가 매우 우수함을 알 수 있었다(도 4 참조).As a result, as shown in Table 5, it was confirmed that the alkaline water according to the present invention has an effect of decomposing melamine, and in particular, even at a low concentration of 1%, it was found to reduce the content of melamine by 54%. In the case of% the content of melamine was not detected. Therefore, through the above results, the alkaline water of the present invention was found to have a very good effect of decomposing melamine (see FIG. 4).
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far I looked at the center of the preferred embodiment for the present invention. Those skilled in the art will appreciate that the present invention can be implemented in a modified form without departing from the essential features of the present invention. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the scope will be construed as being included in the present invention.
도 1은 본 발명에 따른 알칼리수 제조용 미네랄 조성물의 항균성을 테스트한 결과를 나타낸 것이다(A: 대조군, B: 본 발명의 조성물을 투여한 실험군).Figure 1 shows the results of testing the antimicrobial properties of the mineral composition for producing alkaline water according to the present invention (A: control group, B: experimental group administered the composition of the present invention).
도 2는 본 발명의 방법에 따라 제조된 알칼리수 및 종래의 알칼리수들에 의해 세균 증식이 억제되는 양상을 비교한 결과이다.Figure 2 is a result of comparing the bacterial growth is suppressed by the alkaline water and the conventional alkaline water prepared according to the method of the present invention.
도 3은 본 발명의 방법에 따라 제조된 알칼리수 및 종래의 알칼리수를 각각 음용한 후 시간별로 체내의 혈중 활성산소의 농도변화를 비교하여 나타낸 결과이다.Figure 3 is a result of comparing the concentration of free radicals in the blood for each time after drinking the alkaline water and the conventional alkaline water prepared according to the method of the present invention.
도 4는 본 발명의 방법에 따라 제조된 알칼리수의 함량에 따른 멜라민 분해 효과를 나타낸 그래프이다. Figure 4 is a graph showing the melamine decomposition effect according to the content of alkaline water prepared according to the method of the present invention.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090012605A KR101113067B1 (en) | 2009-02-16 | 2009-02-16 | Composition for preparing alkali water and method for producing alkali water using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090012605A KR101113067B1 (en) | 2009-02-16 | 2009-02-16 | Composition for preparing alkali water and method for producing alkali water using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100093427A KR20100093427A (en) | 2010-08-25 |
| KR101113067B1 true KR101113067B1 (en) | 2012-02-16 |
Family
ID=42757844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090012605A KR101113067B1 (en) | 2009-02-16 | 2009-02-16 | Composition for preparing alkali water and method for producing alkali water using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101113067B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200078965A (en) | 2018-12-24 | 2020-07-02 | 조이바이오 주식회사 농업회사법인 | High-purity silicon use Manufacture Water-soluble Alkari salt, The that Manufactured Alkari-water |
| KR102251461B1 (en) | 2020-12-15 | 2021-05-13 | 조이바이오 주식회사 농업회사법인 | High-purity silicon and bay salt use Manufacture Water-soluble Alkari salt, The that Manufactured Alkari-water |
| KR20230020092A (en) | 2021-08-03 | 2023-02-10 | (주)퓨어나인스테이션 | A molding compound having an alkali reduction function and an alkali reduction container molded using the same |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104489832A (en) * | 2014-12-10 | 2015-04-08 | 汤杰永 | Alkalescent drinking water prepared from alkaline substances extracted from vegetables |
| KR102210862B1 (en) * | 2020-04-28 | 2021-02-03 | 주식회사 장수샘물 | Method for manufacturing sports drink composition and functional sports drink |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091113A (en) | 1993-02-17 | 1994-08-24 | 顾宗义 | Purify, the preparation method and its usage of softening, activation, polarized water |
-
2009
- 2009-02-16 KR KR1020090012605A patent/KR101113067B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091113A (en) | 1993-02-17 | 1994-08-24 | 顾宗义 | Purify, the preparation method and its usage of softening, activation, polarized water |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200078965A (en) | 2018-12-24 | 2020-07-02 | 조이바이오 주식회사 농업회사법인 | High-purity silicon use Manufacture Water-soluble Alkari salt, The that Manufactured Alkari-water |
| KR102251461B1 (en) | 2020-12-15 | 2021-05-13 | 조이바이오 주식회사 농업회사법인 | High-purity silicon and bay salt use Manufacture Water-soluble Alkari salt, The that Manufactured Alkari-water |
| KR20230020092A (en) | 2021-08-03 | 2023-02-10 | (주)퓨어나인스테이션 | A molding compound having an alkali reduction function and an alkali reduction container molded using the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100093427A (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2492146C2 (en) | Method of enriching water with oxygen by electrolytic process, oxygen-enriched water or beverage and use thereof | |
| RU2140881C1 (en) | Water produced by electrolysis and containing dissolved hydrogen, method of water production by electrolysis and plant for water production by electrolysis | |
| KR101120942B1 (en) | Manufacturing device of hydrogen water with functional | |
| EP0752391B1 (en) | Production method of water for medical treatment | |
| EP2456327B1 (en) | A process for producing water enriched with natural orthosilicic acid, still water obtained by the said process, cosmetic and therapeutic use of said water | |
| KR101113067B1 (en) | Composition for preparing alkali water and method for producing alkali water using the same | |
| JP3207696U (en) | Oral rehydration equipment | |
| CN101481168A (en) | Drinking water purification treatment material, and manufacturing method and use thereof | |
| CN106629899A (en) | Water purifying and disinfection effervescent tablets and preparation method thereof | |
| KR101261875B1 (en) | Manufacturing Device of Hydrogen Water And Ozone Water With Functional | |
| KR100993571B1 (en) | Process for preparation of mineral-containing water and mineral-containing water prepared by the same | |
| KR102517659B1 (en) | Saltwater salt and its manufacturing method | |
| KR100765907B1 (en) | Antimicrobial and deodorizing composition using inorganic ion of deep sea water | |
| JP2001314877A (en) | Water similar to living body water and method for manufacturing the same | |
| KR101119645B1 (en) | A functional beverage composition comprising deep sea water, taurine, vitamins, royal jelly and propolis as main ingredients | |
| KR101772403B1 (en) | Mineral water manufacturing method | |
| KR100543574B1 (en) | Mineral substance and Preparing method thereof | |
| JPH11315028A (en) | Electrolytic production of water decreasing lipid content in human liver | |
| JP2001302530A (en) | Reduction type antioxidant and method for producing the same | |
| KR20100111062A (en) | Composition for decomposing melamine | |
| KR101068973B1 (en) | How to get rid of harmful ingredients of sulfur | |
| CN106882863A (en) | A kind of preparation method of selenium-rich anion water | |
| KR20170017512A (en) | Manufacturing method of tablets for antioxidant and physical structure care and the product thereof | |
| US6365162B1 (en) | Body cosmetic pigment composition and its production method | |
| CN112806510A (en) | Mineral water and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20150127 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160324 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20170125 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20190117 Year of fee payment: 8 |